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RM
l
F
E
N
a
b
c
d
e
f
g
h
i
j
k
l
m
n
a
A
R
R
A
K
C
A
i
N
T
S
T
1
k
T
f
h
0
bLung Cancer 87 (2015) 89–95
Contents lists available at ScienceDirect
Lung  Cancer
jou rn al hom epage: www.elsev ier .com/ locate / lungcan
eview
anagement  of  crizotinib  therapy  for  ALK-rearranged  non-small  cell
ung  carcinoma:  An  expert  consensus
ederico  Cappuzzoa,∗, Denis  Moro-Sibilotb, Oliver  Gautschic, Ekaterini  Boletid,
nriqueta  Felipe, Harry  J.M.  Groenf, Paul  Germonprég,  Peter  Meldgaardh,  Edurne  Arriola i,
icola  Steele j,  Jesme  Foxk,  Patrick  Schnell l, Arne  Engelsbergm,  Jürgen  Wolfn
Istituto Toscano Tumori, Livorno, Italy
Hôpital A. Michallon, Centre Hospitalier Universitaire, Grenoble, France
Department of Oncology, Luzerner Kantonsspital, Luzern, Switzerland
The Royal Free Hospital, London, United Kingdom
Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
University of Groningen and University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands
AZ Maria Middelares, Ghent, Belgium
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
Hospital del Mar, Barcelona, Spain
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
The Roy Castle Lung Cancer Foundation, Liverpool, United Kingdom
Pﬁzer Oncology, New York, NY, USA
Pﬁzer Oncology, Pﬁzer Pharma GmbH, Berlin, Germany
Department of Internal Medicine, Centre for Integrated Oncology, University Hospital of Cologne, Cologne, Germany
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 4 August 2014
eceived in revised form 8 December 2014
ccepted 14 December 2014
eywords:
rizotinib
naplastic lymphoma kinase (ALK)
nhibitor
on-small cell lung cancer (NSCLC)
herapy management
a  b  s  t  r  a  c  t
Within  4 years  of  the  discovery  of anaplastic  lymphoma  kinase  (ALK)  rearrangements  in non-small  cell
lung  cancer  (NSCLC),  the  ALK inhibitor  crizotinib  gained  US  and  European  approval  for  the  treatment
of  advanced  ALK-positive  NSCLC.  This  was  due  to  the  striking  response  data observed  with crizotinib
in  phase  I  and  II trials  in  patients  with  ALK-positive  NSCLC,  as  well  as  the favorable  tolerability  and
safety  proﬁle  observed.  Recently  published  phase  III data  established  crizotinib  as a  new  standard  of
care  for  this  NSCLC  molecular  subset.  A  consequence  of such  rapid approval,  however,  is  the  limited
clinical  experience  and  relative  paucity  of  information  concerning  optimal  therapy  management.  In  this
review,  we  discuss  the  development  of  crizotinib  and  the  clinical  relevance  of its  safety  proﬁle,  examin-
ing  crizotinib-associated  adverse  events  in  detail  and  making  speciﬁc  management  recommendations.
Crizotinib-associated  adverse  events  were  mostly  mild  to  moderate  in severity  in clinical  studies,  andafety proﬁle
reatment beyond progression
appropriate  monitoring  and  supportive  therapies  are  considered  effective  in avoiding  the  need  for  dose
interruption  or  reduction  in most  cases.  Therapy  management  of patients  following  disease  progres-
sion  on  crizotinib  is also  discussed.  Based  on available  clinical  data,  it is evident  that  patients  may  have
prolonged  beneﬁt  from  crizotinib  after  Response  Evaluation  Criteria  in  Solid  Tumors-deﬁned  disease
progression,  and  crizotinib  should  be continued  for  as  long  as  the  patient  derives  beneﬁt.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. IntroductionRearrangements of the gene encoding the receptor tyrosine
inase anaplastic lymphoma kinase (ALK) in non-small cell lung
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cancer (NSCLC) were identiﬁed in 2007 and shown to contribute to
carcinogenesis in a subgroup of lung cancer patients [1–3]. While
only 3–5% of NSCLC tumors are ALK-rearrangement-positive [1,2,4],
this translates into a considerable number of patients affected
worldwide.
Crizotinib (XALKORI; Pﬁzer Inc., New York, NY, USA) is
an inhibitor of ALK, MET, and ROS1 [5–7]. Crizotinib gained
approval in the US for the treatment of adults with ALK-positive
advanced NSCLC within 4 years of the discovery of the impor-
tance of ALK rearrangement and has subsequently been approved
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Fig. 1. Best percentage change in target lesions from baseline in 133 patients with ALK-positive NSCLC who  received crizotinib in PROFILE 1001. Excludes patients with early
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attributed to crizotinib by investigators include hepatic failure,eath before re-imaging, non-measurable non-target disease, or indeterminate resp
f  crizotinib in patients with ALK-positive non-small-cell lung cancer: updated resu
ultinationally [8]. Crizotinib has since become a recommended
tandard of care for ALK-positive lung cancer in European [9] and
S NSCLC treatment guidelines [10]. The rapid approval of crizo-
inib was granted on the basis of consistent efﬁcacy ﬁndings from
hase I and II clinical trials, coupled with a favorable toxicity
roﬁle and concurrent development of a diagnostic test for ALK
earrangement. In the most recent update from the phase I study,
ROFILE 1001, the objective response rate (ORR) was  61% with a
edian progression-free survival (PFS) of 9.7 months and a median
uration of response of 49 weeks among 143 evaluable patients
11]. Preliminary estimates of overall survival were 88% and 75% at
 and 12 months, respectively, and the majority of patients expe-
ienced tumor shrinkage (Fig. 1) [11]. A single-arm, multicenter
hase II study in patients with advanced previously treated ALK-
ositive NSCLC (PROFILE 1005) reported similar ﬁndings. Crizotinib
as associated with an ORR of 60%, a median duration of response
f 46 weeks, and a median PFS of 8.1 months among 259 evalu-
ble patients [12]. A reduction in key lung cancer-related symptoms
ncluding cough, pain, and dyspnea was also observed [13].
A phase III trial, PROFILE 1007 (N = 347), compared standard
hemotherapy (docetaxel or pemetrexed) with crizotinib as
econd-line treatment for advanced/metastatic ALK-positive NSCLC
14]. The median PFS with crizotinib was 7.7 months versus 3.0
onths with chemotherapy (hazard ratio, 0.49; p < 0.0001); the
RR with crizotinib was more than three times that observed
ith chemotherapy (65% vs. 20%, p < 0.0001). In comparison with
hemotherapy, crizotinib improved symptom control and quality of
ife [14]. For patients who received pemetrexed in the chemother-
py arm of PROFILE 1007, PFS was longer (4.2 months vs. 2.6
onths) and the ORR was higher (30% vs. 9%) than for patients who
eceived docetaxel. More recently, results from a ﬁrst-line phase III
rial in ALK-positive NSCLC, PROFILE 1014, revealed the superior-
ty of crizotinib vs. pemetrexed plus cisplatin or carboplatin [15].
he median PFS was 10.9 months for crizotinib vs. 7.0 months for
hemotherapy (hazard ratio, 0.45; p < 0.0001). The treatment effect
n PFS was in favor of crizotinib for all subgroups analyzed, includ-
ng patients with brain metastases at baseline. In this study, thes. Adapted from The Lancet Oncology, Vol. 13, Camidge DR, et al., Activity and safety
m a phase 1 study, p. 1013, Copyright 2012 [11] with permission from Elsevier.
ORR was 74% with crizotinib and 45% in the control arm (p < 0.0001)
[16].
As a consequence of the rapid approval of crizotinib for patients
with ALK-positive NSCLC, there is limited clinical experience and a
paucity of information concerning optimal therapy management.
The aim of this publication is to provide guidance for clinicians
on the appropriate use of crizotinib and management of its asso-
ciated adverse events (AEs). This report reﬂects consensus views
put forward during a European Crizotinib Therapy Management
Advisory Board meeting held on March 22, 2013 in Frankfurt,
Germany.
2. Management of adverse events
2.1. General safety proﬁle
To date, the most commonly reported AEs (occurring in >25%
of patients) with crizotinib across clinical trials (PROFILE 1001,
PROFILE 1005, and PROFILE 1007) are visual disturbances, nausea,
diarrhea, vomiting, edema, elevated transaminases, constipation,
and fatigue, with most events being grade 1/2 in severity [8,14].
The most frequently reported AEs in PROFILE 1007 [14] are listed
in Table 1. The incidence of treatment-related AEs leading to dis-
continuation with crizotinib was  2% (PROFILE 1001), 4% (PROFILE
1005), and 6% (PROFILE 1007) [8,14]. Sinus bradycardia was  also
very commonly observed, although it was  not always reported as
an AE since it was  usually asymptomatic [8,17]. Other important
but less common toxicities included pneumonitis [8,11,14], QTc
prolongation [8,14], and severe hepatotoxicity [8,18]. In addition,
in male patients hypogonadism was  reported to occur as a conse-
quence of crizotinib treatment [19]. Events with a fatal outcomepneumonitis, and ventricular arrhythmia [14,18]. Elevated levels
of alanine aminotransferase (ALT; grades 1–4, 71%) and aspartate
aminotransferase (AST; grades 1–4, 61%) were commonly observed
in crizotinib clinical trials [4,11,12,14].
F. Cappuzzo et al. / Lung Can
Table  1
Adverse events of any cause in PROFILE 1007 that occurred in ≥15% of patients in
either treatment arm and differed in incidence by ≥5%.a
Adverse event n (%)
Crizotinib (N = 172) Chemotherapy (N = 171)
Any grade Grade 3/4 Any grade Grade 3/4
Vision disorderb,c 103 (60) 0 16 (9) 0
Diarrhead 103 (60) 0 33 (19) 1 (<1)
Nausead 94 (55) 2 (1) 64 (37) 1 (<1)
Vomitingd 80 (47) 2 (1) 30 (18) 0
Constipation 73 (42) 4 (2) 39 (23) 0
Elevated
aminotransferase
levelsb
66 (38) 27 (16)e 25 (15) 4 (2)
Edemab 54 (31) 0 27 (16) 0
Fatigue 46 (27) 4 (2) 57 (33) 7 (4)
Upper respiratory
tract infectionb
44 (26) 0 22 (13) 1 (1)
Dysgeusia 44 (26) 0 16 (9) 0
Dizzinessb 37 (22) 1 (1) 14 (8) 0
Dyspneab,f 23 (13) 7 (4) 32 (19) 5 (3)
Rash 15 (9) 0 29 (17) 0
Alopecia 14 (8) 0 35 (20) 0
From The New England Journal of Medicine, Shaw AT, et al., Crizotinib versus
chemotherapy in advanced ALK-positive lung cancer, Vol. 368, p. 2391 [14]. © (2013)
Massachusetts Medical Society. Adapted with permission from Massachusetts Med-
ical Society.
a Not adjusted for the longer duration of treatment of crizotinb (31.0 weeks)
versus chemotherapy (12.3 weeks).
b Item comprised a cluster of adverse events that may  represent similar clinical
symptoms or syndromes.
c Vision disorders included (in descending order of frequency) visual impairment,
photopsia, blurred vision, vitreous ﬂoaters, halo vision or photophobia, chromatop-
sia  or diplopia, and reduced visual acuity.
d The use of antiemetic agents was signiﬁcantly higher in the chemotherapy group
than in the crizotinib group (67% vs. 20%).
e Included one case meeting the criteria for Hy’s law (serum bilirubin level
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w3  × upper limit of normal in the absence of biliary obstruction or Gilbert’s syn-
rome) with grade 5 hepatic failure occurring after the cut-off date.
f One case of grade 5 dyspnea was reported in each treatment group (<1% of
atients in each group).
.2. Vision disorder
Grade 1/2 visual disturbances were the most frequently
eported AEs across crizotinib clinical trials (59–62%) [4,11,12,14].
hese included visual impairment, photopsia, blurred vision, vitre-
us ﬂoaters, photophobia, and diplopia. In practice, patients often
eport visual disturbances as ﬂashes of light or trailing lights in
heir peripheral vision, overlapping shadows, or after-images, most
ommonly occurring during adaptation to changes in lighting con-
itions (dim or bright) [20]. In PROFILE 1005, the proportions of
atients reporting visual effects diminished with increasing time
n crizotinib treatment: cycle 2, 65%; cycle 3, 58%; cycle 4, 55%; and
ycle 5, 50% [21]. In general, visual disturbances were reported as
ransient (either <30 s or 30–60 s) and as either not or a little both-
rsome, with little or no impact on their activities of daily living
Fig. 2) [21].
Electroretinography studies in rats have provided evidence
f a direct effect of crizotinib on retinal function, speciﬁcally a
ecreased rate of dark adaptation [22]. Since visual disturbances
re generally transient, are not found to be bothersome, and do not
ffect patients’ quality of life, they do not require speciﬁc inter-
ention. However, opththalmologic and/or neurologic evaluation
hould also be considered if visual disturbances persist or worsen in
everity during crizotinib treatment in order to exclude unrelated
etinal pathology, optic nerve pathology, or CNS involvement of
nderlying NSCLC. Treating physicians should discuss visual distur-
ances with their patients prior to initiating crizotinib treatment,
nd patients should be aware that this might potentially interfere
ith certain activities (e.g. when driving in the dark).cer 87 (2015) 89–95 91
2.3. Gastrointestinal toxicity
Crizotinib-associated gastrointestinal toxicities include nausea
(47–57%), vomiting (39–47%), diarrhea (41–60%), and constipa-
tion (28–42%) [4,11,12,14]. These are generally mild or moderate
(grade 1/2); across clinical studies to date, fewer than 1% of each
of these toxicities were grade 3/4. Nausea and vomiting generally
occur early in treatment, with a median time to ﬁrst onset of 2–3
days (range 1–518). During treatment, the prevalence of common
treatment-related grade 1 gastrointestinal AEs decreased over time
[11].
Gastrointestinal toxicities can usually be managed with sup-
portive care rather than crizotinib dose reduction or interruption;
however, in rare cases, dose reduction may  be necessary. As speci-
ﬁed in the Summary of Product Characteristics (SmPC), there is only
a minor food effect on the absorption of crizotinib; hence, it can be
administered with and without food [8]. Some physicians report
that vomiting may  occur more frequently in the morning and can
be ameliorated by taking crizotinib with or after meals and/or with
concomitantly administered antiemetics, such as metoclopramide.
Serotonin 5-HT3 receptor antagonists (for example, ondansetron)
should be used with caution because they can prolong the QT
interval, which is an AE observed with crizotinib (see Section 2.4).
Diarrhea can generally be managed with loperamide or codeine
phosphate. If dose reduction is warranted, crizotinib should be
reduced to 200 mg  twice daily [8]. If further reduction is necessary,
the dose should be modiﬁed to 250 mg  once daily [8].
2.4. Cardiac toxicity
Bradycardia and QTc prolongation have been observed with
crizotinib treatment [8,14,17]. While QTc prolongation is observed
with other kinase inhibitors [23], bradycardia is relatively unique
to crizotinib [17]. In a retrospective analysis of 42 crizotinib-treated
patients enrolled in PROFILE 1001 and PROFILE 1005, the aver-
age on-treatment heart rate reduction relative to baseline was
26.1 beats per minute (bpm) [17]. Additionally, 69% of patients
experienced at least one episode of sinus bradycardia (heart rate
≤60 bpm), although this was asymptomatic in all cases. Mean time
to the lowest heart rate was  18.6 weeks. Patients at higher risk for
sinus bradycardia were older (55.8 years vs. 47.8 years; p = 0.0336)
and had a lower pretreatment heart rate (mean, 77.9 vs. 100.6 bpm;
p = 0.002) [17].
In terms of QTc prolongation, 1.4% of 1167 patients were
found to have a QTc ≥500 ms,  and 4.4% of 1136 patients
had an increase from baseline QTc of ≥60 ms as measured
by automated machine-read electrocardiogram (ECG) [24]. A
pharmacokinetic–pharmacodynamic analysis suggested a crizo-
tinib concentration-dependent increase in the QTc [24].
At the current time, the clinical signiﬁcance and long-term
effects of crizotinib-associated bradycardia and QTc prolongation
are not fully understood. However, crizotinib should be used cau-
tiously in patients who  have a history of or predisposition for QTc
prolongation [8]. Moreover, the risk of QTc prolongation may be
increased because of electrolyte disturbances secondary to vomit-
ing, diarrhea, or impaired renal function. ECG monitoring should be
considered in patients with a history of cardiac disease, and in those
taking medications with the potential for QTc prolongation. In high-
risk patients, measuring QTc under optimal conditions (possibly
in triplicate) at baseline and during treatment might be advisable.
Symptoms such as dizziness, palpitations, syncope, seizures, or
unexplained loss of consciousness, as well as electrolyte imbalance
(e.g. caused by gastrointestinal toxicity), may also be considered
triggers for additional ECG monitoring. In the case of grade 3 QT
prolongation (≥501 ms  on at least two  separate ECGs [25]), treat-
ment should be temporarily discontinued until recovery to grade
92 F. Cappuzzo et al. / Lung Cancer 87 (2015) 89–95
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observed after starting crizotinib can be successfully re-challenged
with a lower dose following recovery after dose interruption. The
SmPC recommends withholding treatment until recovery to grade
≤1, resuming at 200 mg  twice daily in the case of grade 3/4 ALT or
Table 2
Hepatic laboratory abnormalities with crizotinib in PROFILE 1001 and PROFILE 1005
(N  = 1054) [18].
Parameter nb Proportion of patients by CTCAEa grade, %
Grade 1 Grade 2 Grade 3 Grade 4 Grades 1–4
ALT 1004 50.7 12.8 5.8 1.6 70.9
AST 1005 51.4 6.7 2.7 0.5 61.3
AP  1004 53.0 9.5 2.3 0 64.7
TBL  1005 2.1 1.1 0.4 0 3.6ig. 2. Patient-reported impact of visual disturbances with crizotinib on activities 
iving.  Adapted from Besse B et al., 2012 [21] with the author’s permission.
1, resumed at 200 mg  twice daily, and permanently discontinued
f QT prolongation recurs or if a grade 4 event is observed [8].
Bradycardia may  lead to clinical symptomatology, including
izziness, syncope, hypotension, and fatigue, particularly in the
lderly or in patients also receiving antihypertensive medications.
herefore, use of concomitant medications associated with brady-
ardia (e.g. beta blockers) should be carefully evaluated prior to
nd during crizotinib treatment. According to the current US pre-
cribing information [24], crizotinib should be withheld in the
vent of symptomatic bradycardia until recovery to asymptomatic
radycardia or a heart rate ≥60 bpm, and concomitant medications
nown to cause bradycardia, as well as antihypertensive medica-
ions, should be evaluated. If contributing concomitant medication
s identiﬁed and discontinued or dose-adjusted, crizotinib can be
esumed at the previous dose upon recovery to asymptomatic
radycardia or a heart rate ≥60 bpm. If no contributing concomitant
edication is identiﬁed, or if contributing concomitant medica-
ions are not discontinued or dose-modiﬁed, crizotinib can be
esumed at a reduced dose upon recovery to asymptomatic brady-
ardia or a heart rate ≥60 bpm [24]. In cases of life-threatening
radycardia, crizotinib should be permanently discontinued unless
 contributing concomitant medication is identiﬁed. In this case,
rizotinib can be resumed at 250 mg  once daily upon recovery to
symptomatic bradycardia or a heart rate of ≥60 bpm with frequent
onitoring [24].
.5. Hepatotoxicity
Elevated ALT levels were reported in 38% of crizotinib-treated
atients in PROFILE 1007, and 16% of crizotinib-treated patients had
rade 3/4 ALT elevations [14]. Detailed laboratory analysis of blood
amples from over 1000 patients from PROFILE 1001 and PROFILE
005 showed frequent liver enzyme elevations (Table 2 [18]), gen-
rally occurring in the ﬁrst 2 months of treatment [4,11,12,18].
LT and AST elevations were evident in 70.9% and 61.3% of cases,
espectively, and were grade 3 or 4 in 7.4% and 3.2% of cases,
espectively [18]. In this analysis, temporary discontinuations or
ose reductions due to hepatic AEs occurred in 5.3% of patients.
lthough permanent discontinuations were necessary in 1.3% of
atients, transaminase elevations were generally reversible, allow-
ng patients to continue at the same or a lower dose [18]. Asy living in PROFILE 1005. a0, no effect; 10, completely prevented activities of daily
of March 31, 2013, a total of 16 cases of severe, possibly drug-
induced liver injury (elevation of ALT to ≥3 × upper limit of normal
[ULN] and concurrent or subsequent elevation of total bilirubin to
≥2 × ULN in the absence of biliary obstruction, hemolysis, or any
evident or likely explanation of these ﬁndings other than crizotinib
treatment) have been reported from clinical studies, spontaneous
sources, or compassionate use (Pﬁzer Inc., data on ﬁle).
Severe hepatic impairment, as deﬁned by a bilirubin of >3 × ULN
regardless of ALT/AST, is listed as a contraindication in the SmPC,
based on the above-mentioned liver toxicity and in the absence of
systematic data in this population [8]. A clinical study of crizotinib
in severely hepatically impaired patients is currently ongoing. Mon-
itoring of liver enzymes and total bilirubin every week for the ﬁrst
2 months of crizotinib therapy (with monthly monitoring and as
clinically indicated thereafter) should be performed, as speciﬁed in
the SmPC [8]. Furthermore, patients should be educated about signs
and symptoms of drug-induced liver injury and hepatic failure.
Initiation and withdrawal of crizotinib treatment should be
made on a case-by-case basis and take into account clinical factors,
as well as laboratory data. For example, a patient with elevated
total bilirubin may  beneﬁt from crizotinib if the higher total biliru-
bin levels are caused by biliary obstruction due to liver metastases.
Most patients in whom signiﬁcantly elevated hepatic enzymes areALT, alanine transaminase; AP, alkaline phosphatase; AST, aspartate transaminase;
CTCAE, Common Terminology Criteria for Adverse Events; TBL, total bilirubin.
a PROFILE 1001, CTCAE v3.0; PROFILE 1005, CTCAE v4.0.
b Number of patients with available laboratory data.
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ST elevation with concurrent grade ≤1 total bilirubin elevation;
nd permanent discontinuation for patients with grade ≥2 ALT or
ST elevation with concurrent grade ≥2 total bilirubin elevation
in the absence of cholestasis or hemolysis) [8]. To date, no factors
ssociated with an increased risk of developing crizotinib-induced
epatotoxicity have been identiﬁed.
.6. Hypogonadism
A rapid reduction in testosterone levels has been observed
ithin 14–21 days of crizotinib treatment. This was found to be
eversible after stopping crizotinib [19]. In one report, mean total
estosterone levels were 25% below the lower limit of normal (LLN)
n 27 of 32 crizotinib-treated patients (84%) versus 29% above LLN in
ix of 19 non-crizotinib-treated patients (32%; p = 0.0012). In addi-
ion to reductions in the levels of two major testosterone-binding
roteins (albumin and sex hormone-binding globulin), levels of
uteinizing hormone and follicle-stimulating hormone levels also
eclined rapidly, suggesting that crizotinib may  have a centrally
ediated effect [26]. In total, 84% and 79% of crizotinib-treated
atients with low free and low total testosterone levels, respec-
ively, manifested symptoms consistent with androgen deﬁciency
26]. Notably, in addition to sexual dysfunction, fatigue may  be a
ommon symptom of low testosterone.
As a consequence of these observations, the potential for
ypogonadism should be discussed with male patients prior to
nitiating crizotinib treatment. Monitoring testosterone levels in
atients with potential symptoms of hypogonadism was sug-
ested by the advisory board, along with referral of patients with
ow levels to an endocrinologist, without changing the crizotinib
osage. Testosterone replacement therapy may  be recommended
y endocrinologists, although the risk–beneﬁt ratio should be care-
ully considered [27].
.7. Other adverse events
Approximately 30% of crizotinib-treated patients experience
rade 1/2 edema, which was associated with a rather late onset
median onset, 85 days) [11]. Peripheral edema is most commonly
bserved, particularly in women, although facial and periorbital
demas have also been reported. In some patients, crizotinib-
nduced edema appears to be amenable to standard medical or
hysiotherapeutic interventions. While low-grade edema may  be
 common and bothersome event, in the vast majority of cases it
oes not necessitate dose reduction or treatment interruption.
Neutropenia has been reported in 9–14% of crizotinib-treated
atients participating in clinical trials [12] and is also a common
rade 3/4 AE (6–13%) [12], leading to dose reductions in a small
umber of cases [11]. For any grade 3/4 hematologic toxicity except
ymphopenia, the SmPC recommends withholding treatment until
ecovery to grade ≤2, resuming on the same dosing schedule for
atients who had grade 3 hematologic toxicity or at 200 mg  twice
aily for those with grade 4 toxicity [8].
In approximately 1–2% of patients, crizotinib has been associ-
ted with pneumonitis or interstitial lung disease, which can be
evere, life-threatening, or fatal [4,8]. However, symptoms indica-
ive of pneumonitis may  be disease- rather than drug-related and
ay  be caused by NSCLC progression, infection, prior radiation
ffects, or other pulmonary diseases. Any decision to stop crizo-
inib treatment should therefore be made on a case-by-case basis.
f treatment-related pneumonitis is diagnosed, crizotinib should be
ermanently discontinued [8], and standard treatment of intersti-
ial lung disease should be considered.
Complex renal cysts have been reported in 4% of crizotinib-
reated patients [24]. However, a blinded radiologic review of
omputed tomography images of 255 crizotinib-treated patientscer 87 (2015) 89–95 93
revealed new renal cysts in almost 10% of patients (Pﬁzer Inc., data
on ﬁle). There were no reports of associated renal impairment,
and urinalyses were typically normal. Aspirations and biopsies,
when performed, were generally not diagnostic, and to date, no evi-
dence of malignancy has been found. In some cases, local extension
of cysts into adjacent tissues necessitated percutaneous drainage
procedures; however, most patients were able to continue crizo-
tinib without dose modiﬁcation. In a small retrospective analysis,
treatment with crizotinib was shown to be related to a reversible
reduction of the glomerular ﬁltration rate by approximately 20%.
This did not, however, have clinical implications [28].
3. Optimizing duration of treatment
Acquired resistance is a common feature of tyrosine kinase
inhibitor (TKI) therapy due to the selection pressure for clones with
reduced sensitivity to the drug. A number of small studies have
investigated the molecular mechanisms of acquired resistance to
crizotinib and have unveiled a striking heterogeneity of molec-
ular events underlying this process [29–31]. In 25–43% of cases,
secondary point mutations have been identiﬁed in ALK, conferring
resistance to crizotinib. An in vitro mutagenesis screen of crizotinib
in NSCLC cells identiﬁed similar mutations [32]. Other mecha-
nisms of acquired resistance include ALK copy-number gain (with
or without additional ALK mutation), as well as ALK-non-dominant
mechanisms including point mutation of KRAS, EGFR, and ampliﬁ-
cation of KIT [29–31]. Furthermore, separate cases of coexistence of
ALK-dominant and non-dominant mechanisms of resistance have
been identiﬁed in patients (ALK mutation with KIT ampliﬁcation
and ALK copy-number gain with EGFR mutation) [30,31]. In a sig-
niﬁcant number of cases the mechanism of resistance is unknown.
Different clinical scenarios of progression under crizotinib treat-
ment have been observed: (1) rapid symptomatic progression,
(2) formation of a single new lesion or increased size of a sin-
gle lesion that was  previously under control (oligoprogression),
and (3) slow asymptomatic growth of multiple lesions that were
formerly controlled with crizotinib. In this context it is interest-
ing that cessation of TKI therapy in NSCLC with activating EGFR
mutations has been documented to cause disease ﬂare in 23% of
patients with acquired resistance to EGFR TKIs following washout
of the drug [33]. Although this phenomenon has not been system-
atically evaluated for EML4-ALK translocations and crizotinib, two
case reports document a similar phenomenon following crizotinib
withdrawal at disease progression in patients with ALK-positive
metastatic NSCLC [34,35].
Single new or newly growing lesions can potentially be con-
trolled by local treatment such as stereotactic radiotherapy or even
surgery when all other disease areas remain controlled by crizo-
tinib [36]. When alternative signaling pathways get activated, the
tumor remains at least partly driven by the ALK rearrangement.
In both cases, withdrawal of crizotinib bears the risk of restarted
or enhanced tumor proliferation since aberrant ALK remains the
major oncogenic driver.
In a small series of patients (n = 25), Weickhardt et al. demon-
strated a median additional 6.2 months of PFS when erlotinib or
crizotinib were continued beyond a progression event, which was
treated locally (surgery or radiotherapy). Interestingly, there was
a trend toward a larger beneﬁt for patients who had progression
the CNS only [37]. In a follow-up analysis of crizotinib-treated
patients with ALK-positive NSCLC, Gan and coauthors showed
that local control of up to 4 newly growing lesions outside the
CNS with local ablative approaches allowed an additional median
5.5 months of PFS with crizotinib, which was  also associated
with a longer overall survival. Although not statistically signiﬁ-
cant, this approach appeared to be more successful for patients
with 1 or 2 progression lesions compared to 3 or 4 [36]. In
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[1] Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling
identiﬁes oncogenic kinases in lung cancer. Cell 2007;131:1190–203.
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ddition, Ou and coauthors showed longer survival among those
atients who stayed on crizotinib post-Response Evaluation Crite-
ia in Solid Tumors (RECIST)-deﬁned progressive disease (PD) [38].
n this retrospective analysis involving 194 patients from PRO-
ILE 1001 and PROFILE 1005, overall survival was  signiﬁcantly
onger among patients who continued crizotinib treatment beyond
ECIST-deﬁned PD than among those who did not, both from the
ime of PD (median 16.4 vs. 3.9 months, respectively; p < 0.0001)
nd from initiation of crizotinib treatment (median 29.6 vs. 10.8
onths; p < 0.0001) [38]. Additional reports have also suggested
ontinued clinical beneﬁt in this setting [11,39]. Although all of
hese analyses are retrospective and subject to a potential selec-
ion bias, they provide evidence that there is substantial value from
ontinued crizotinib for individual patients who are candidates for
ocal therapy at a progression event. The advisory board consen-
us opinion was that crizotinib should be continued for as long as
he patient derives beneﬁt from treatment. The decision to stop
reatment should not be based only on radiography but should take
he clinical situation into consideration. Treatment should be dis-
ontinued when symptomatic and/or rapid progression occurs and
f other treatment options are available, such as chemotherapy or
ovel agents in clinical trials.
Ideally, treatment plans for patients with disease progression
n crizotinib should be individualized based upon clinical proﬁles,
ncluding the magnitude of prior response, number and location
f metastatic sites, and remaining tumor burden. In select cases
f oligometastatic progression, integration of crizotinib and other
ocal therapeutic options such as surgery, radiofrequency abla-
ion, and radiotherapy should be considered. In addition, treatment
f isolated brain metastases with radiotherapy or local ablative
herapy with subsequent continued crizotinib therapy has shown
romise [37,39]. For single liver metastasis, surgery or local abla-
ion may  be appropriate therapies depending upon tumor volume.
imilarly, extent of disease inﬂuences the management of patients
ith bone metastases, with continued crizotinib and intermittent
rradiation probably being appropriate for patients with single
esions only. Once a local recurrence is controlled using other
odalities, crizotinib remains effective in controlling the primary
isease in many cases. However, clinical studies assessing the ben-
ﬁt derived from crizotinib in combination with local therapy in a
rospective setting are warranted to enable deﬁnitive recommen-
ations to be made.
In early clinical trials, the second generation ALK inhibitors
eritinib and alectinib have demonstrated marked activity in ALK-
ositive NSCLC after failure of crizotinib with an ORR of 56% and
5%, respectively [40,41]. Based on these data, ceritinib has recently
een approved by the US FDA for the treatment of patients with
LK-positive NSCLC who have progressed on or are intolerant to
rizotinib. Following failure of crizotinib, ceritinib and alectinib
an be a treatment option when access to these compounds is
vailable. Unless it has been used in the ﬁrst-line before crizo-
inib, pemetrexed is the otherwise preferred medical treatment in
he resistance situation based on accumulating evidence of its efﬁ-
acy in ALK-positive NSCLC [14]. If pemetrexed was used before,
ocetaxel is another option. Cases of successful re-challenge with
rizotinib have been described after chemotherapy [42].
. Conclusion
The rapid development of crizotinib from experimental com-
ound to approved therapy has had a major impact on the lives
f patients with ALK-positive NSCLC. However, a consequence of
uch rapid approval is limited experience and information concern-
ng management of AEs and long-term therapy management. This
eport summarizes consensus opinion developed during a Euro-
ean Crizotinib Therapy Management Advisory Board meeting. Thecer 87 (2015) 89–95
opinion was  that crizotinib was generally well tolerated. AEs were
mostly mild to moderate in severity, and appropriate monitoring
and supportive therapies were considered effective in avoiding the
need for dose interruption or reduction in most cases.
Mild visual disturbances are the most common side effect
associated with crizotinib and, while rarely bothersome, patients
should be advised to exercise caution when driving or operat-
ing machinery; if symptoms worsen, further investigation may
be appropriate. ECG monitoring is recommended to assess possi-
ble QTc prolongation as well as bradycardia in crizotinib-treated
patients. This is particularly important for patients with a his-
tory of cardiac disease, those taking medications with a potential
for QT prolongation, or those with clinically relevant symptoms.
Due to cases of severe hepatoxicity observed in a small number
of crizotinib-treated patients, regular monitoring of liver function
is important. In cases of severe hematologic toxicity, treatment
interruption may  be necessary for some patients.
Based on available clinical data, it is evident that patients may
have prolonged beneﬁt from crizotinib after RECIST-deﬁned PD.
Therefore, crizotinib should be continued for as long as the patient
derives beneﬁt. Local recurrences can be managed using other
modalities, and in many cases crizotinib continues to provide effec-
tive disease control. Crizotinib should be discontinued upon rapid
progression and/or clinical deterioration.
Continued data collection, information sharing, and clinical
trials are essential to optimize AE management and crizotinib
treatment, as well as to manage the impact of the heterogeneous
mechanisms associated with crizotinib resistance.
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